These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 32219971)

  • 1. Use of the esa resistance index to guide dosing for anaemia management.
    Ross EA; Paugh-Miller JL; Wen X; Nappo RW
    J Ren Care; 2020 Dec; 46(4):216-221. PubMed ID: 32219971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort.
    Yong K; Kairaitis L
    Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic dialysis-associated anaemia in end-stage renal disease: analysis of management in two French centres.
    Perrinet M; Décaudin B; Champs BB; Heran I; Urbina MA; Lemaitre V; Azar R; Odou P
    J Clin Pharm Ther; 2010 Aug; 35(4):395-400. PubMed ID: 20831542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoiesis-stimulating agent dosing, haemoglobin and ferritin levels in UK haemodialysis patients 2005-13.
    Birnie K; Caskey F; Ben-Shlomo Y; Sterne JA; Gilg J; Nitsch D; Tomson C
    Nephrol Dial Transplant; 2017 Apr; 32(4):692-698. PubMed ID: 27190350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A predictive algorithm for the management of anaemia in haemodialysis patients based on ESA pharmacodynamics: better results for less work.
    Lines SW; Lindley EJ; Tattersall JE; Wright MJ
    Nephrol Dial Transplant; 2012 Jun; 27(6):2425-9. PubMed ID: 22207330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comorbidity, anemia and response to erythropoiesis stimulating agents in chronic hemodialysis].
    Anaya S; Rivera F; Sánchez de la Nieta MD; Carreño A; Vozmediano C; Alcaide MP; Arambarri M; Nieto J; Caparrós G; Ferreras I
    Nefrologia; 2008; 28(2):186-92. PubMed ID: 18454709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease.
    Carrero JJ; Bárány P; Yilmaz MI; Qureshi AR; Sonmez A; Heimbürger O; Ozgurtas T; Yenicesu M; Lindholm B; Stenvinkel P
    Nephrol Dial Transplant; 2012 Feb; 27(2):709-15. PubMed ID: 21617198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anemia management trends in hospital-based dialysis centers (HBDCs), 2010 to 2013.
    Coritsidis GN; Maglinte GA; Acharya A; Saxena A; Chang CL; Hill J; Gitlin M; Lafayette RA
    Clin Ther; 2014 Mar; 36(3):408-18. PubMed ID: 24582713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individualized anemia management in a dialysis facility - long-term utility as a single-center quality improvement experience
.
    Gaweda AE; Jacobs AA; Aronoff GR; Brier ME
    Clin Nephrol; 2018 Oct; 90(4):276-285. PubMed ID: 30049300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality in incident haemodialysis patients: time-dependent haemoglobin levels and erythropoiesis-stimulating agent dose are independent predictive factors in the ANSWER study.
    Fort J; Cuevas X; García F; Pérez-García R; Lladós F; Lozano J; Martín-Malo A;
    Nephrol Dial Transplant; 2010 Aug; 25(8):2702-10. PubMed ID: 20176608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes in patients with chronic kidney disease not on dialysis receiving extended dosing regimens of darbepoetin alfa: long-term results of the EXTEND observational cohort study.
    Galle JC; Addison J; Suranyi MG; Claes K; Di Giulio S; Guerin A; Herlitz H; Kiss I; Farouk M; Manamley N; Wirnsberger G; Winearls C
    Nephrol Dial Transplant; 2016 Dec; 31(12):2073-2085. PubMed ID: 27190334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Effectiveness of Iron and Erythropoiesis-Stimulating Agent Dosing on Health-Related Quality of Life in Patients Receiving Hemodialysis.
    Freburger JK; Ellis AR; Wang L; Butler AM; Kshirsagar AV; Winkelmayer WC; Brookhart MA
    Am J Kidney Dis; 2016 Feb; 67(2):271-82. PubMed ID: 26508682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studies.
    Akizawa T; Taguchi M; Matsuda Y; Iekushi K; Yamada T; Yamamoto H
    BMJ Open; 2019 Jun; 9(6):e026602. PubMed ID: 31203241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial).
    Kato H; Nangaku M; Hirakata H; Wada T; Hayashi T; Sato H; Yamazaki Y; Masaki T; Kagimura T; Yamamoto H; Hase H; Kamouchi M; Imai E; Mizuno K; Iwasaki M; Akizawa T; Tsubakihara Y; Maruyama S; Narita I
    Clin Exp Nephrol; 2018 Feb; 22(1):78-84. PubMed ID: 28660446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluctuations of haemoglobinaemia in chronic haemodialysis patients.
    De Meester J; Maes B; De Vriese A; De Moor B; Donck J; Helbert M; Bammens B; Jamar S
    Acta Clin Belg; 2011; 66(2):123-8. PubMed ID: 21630609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of dose of erythropoiesis stimulating agents on cardiovascular outcomes, quality of life and costs of haemodialysis. the clinical evaluation of the DOSe of erythropoietins (C.E. DOSE) Trial].
    Saglimbene V; D'Alonzo D; Ruospo M; Vecchio M; Natale P; Gargano L; Nicolucci A; Pellegrini F; Craig JC; Triolo G; Procaccini DA; Santoro A; Di Giulio S; La Rosa S; Murgo A; Di Toro Mammarella R; Sambati M; D'Ambrosio N; Greco V; Giannoccaro G; Flammini A; Boccia E; Montalto G; Pagano S; Amarù S; Fici M; Lumaga GB; Mancini E; Veronesi M; Patregnani L; Querques M; Schiavone P; Chimienti S; Palumbo R; Di Franco D; Della Volpe M; Gori E; Salomone M; Iacono A; Moscoloni M; Treglia A; Casu D; Piras AM; Di Silva A; Mandreoli M; Lopez A; Quarello F; Catizone L; Russo G; Forcellini S; Maccarone M; Catucci G; Di Paolo B; Stingone A; D'Angelo B; Guastoni C; Pasquali S; Minoretti C; Bellasi A; Boscutti G; Martone M; David S; Schito F; Urban L; Di Iorio B; Caruso F; Mazzoni A; Musacchio R; Andreoli D; Cossu M; Li Cavoli G; Cornacchiari M; Granata A; Clementi A; Giordano R; Guastoni C; Barzaghi W; Valentini M; Hegbrant J; Tognoni G; Strippoli GF
    G Ital Nefrol; 2013; 30(2):. PubMed ID: 23832463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).
    Locatelli F; Canaud B; Giacardy F; Martin-Malo A; Baker N; Wilson J
    Nephrol Dial Transplant; 2003 Feb; 18(2):362-9. PubMed ID: 12543893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial.
    Gummer J; Trengove R; Pascoe EM; Badve SV; Cass A; Clarke P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM; Johnson DW; Olynyk JK; Ferrari P;
    Nephrology (Carlton); 2017 Jul; 22(7):548-554. PubMed ID: 27171136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Importance of ultrapure dialysis liquid in response to the treatment of renal anaemia with darbepoetin in patients receiving haemodialysis].
    Molina M; Navarro MJ; Palacios ME; de Gracia MC; García Hernández MA; Ríos Moreno F; Pérez Silva FM
    Nefrologia; 2007; 27(2):196-201. PubMed ID: 17564565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.